No supplement label number raises eyebrows like B12’s: 500 µg per drop — 20,000% NRV. Read through the lens of most vitamins, that looks reckless; read through B12’s actual absorption physiology, it is the textbook-rational dose, arrived at by clinical trials rather than marketing arithmetic. The explanation is one of nutrition science’s most elegant stories — and its punchline is a percentage: one.
Two doors into the body
B12 absorption runs through two entirely different mechanisms. The primary door is the intrinsic factor (IF) pathway: stomach acid frees B12 from food proteins, salivary haptocorrin escorts it, pancreatic enzymes hand it to intrinsic factor (secreted by gastric parietal cells), and the IF–B12 complex is absorbed by specific receptors in the terminal ileum. It is efficient — and tiny: receptor capacity saturates at roughly 1.5–2 µg per meal. Beyond that, a second door opens: passive diffusion across the intestinal wall, requiring no acid, no intrinsic factor, no receptors — absorbing a fixed ~1% of any oral dose, however large. This 1% rule, established in classic isotope studies, is the key that unlocks every dose decision that follows.
The arithmetic of 1%
Daily requirement: ~4 µg (EFSA adequate intake). Now run the doses. A 10 µg tablet: ~2 µg via IF (if that pathway works) + 0.1 µg passive — adequate only when everything upstream is healthy. A 500 µg dose: ~5 µg via passive diffusion alone — the full daily requirement delivered even if stomach acid is suppressed, intrinsic factor is gone, or the ileum’s receptors are compromised. A 1,000–2,000 µg dose: 10–20 µg passively — the range used to treat established deficiency. High-dose oral B12, in other words, is not “more is better”; it is route engineering — deliberately using the door that cannot be closed by age, autoimmunity or acid-suppressing drugs (the risk groups our companion article maps in detail).
The trials: oral equals injection
For decades, compromised IF-pathway patients (pernicious anaemia above all) were told injections were their only option. The landmark randomised trial by Kuzminski and colleagues (Blood, 1998) tested that assumption directly: 2,000 µg oral B12 daily versus a standard intramuscular injection schedule in deficient patients — including IF-deficient ones. Result: oral treatment matched injections haematologically and neurologically, and at several time points produced higher serum B12 levels. The Cochrane systematic review (Vidal-Alaball 2005) and subsequent trials consolidated the verdict: high-dose oral B12 is as effective as intramuscular administration for correcting deficiency. The 1% door, given enough traffic, carries the full load — a conclusion now embedded in clinical guidance across multiple countries.
The safety side: why there is no upper limit
B12 occupies a rare regulatory position: neither EFSA nor the US Institute of Medicine has set a tolerable upper intake level — after systematic review, no intake threshold associated with harm could be identified (EFSA Journal 2015). The physiology explains why: absorption above the IF ceiling is already throttled to 1%; plasma transport requires binding proteins with finite capacity; and the excess is excreted in urine. Doses of 1,000–2,000 µg daily have been used for years in trials without dose-limiting toxicity. “20,000% NRV” therefore describes distance from a deficiency-prevention reference (see our NRV explainer), not proximity to any danger line — for B12, no such line has been found.
The clinical bottom line
B12’s absorption ceiling (~2 µg per meal via intrinsic factor) plus its 1% passive pathway make high oral doses the engineering solution, not an indulgence: 500 µg delivers a full day’s requirement through the door that age, autoimmunity, metformin and acid suppression cannot close — with trial-proven equivalence to injections and no established upper safety limit. The startling percentage on the label is, for once, the physiology speaking. Diagnosed deficiency and pernicious anaemia remain medical conditions: supplementation supports, but never replaces, their proper management.
Primary sources
- Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92(4):1191–1198. doi:10.1182/blood.V92.4.1191
- Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2005;(3):CD004655. doi:10.1002/14651858.CD004655.pub2
- EFSA NDA Panel. Scientific Opinion on Dietary Reference Values for cobalamin (vitamin B12). EFSA Journal. 2015;13(7):4150. doi:10.2903/j.efsa.2015.4150
- Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008;112(6):2214–2221. doi:10.1182/blood-2008-03-040253
- Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040. doi:10.1038/nrdp.2017.40
Educational information on nutrient physiology, not medical advice. Suspected or diagnosed B12 deficiency, and pernicious anaemia in particular, require physician-led diagnosis and management.
Was this article helpful?
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
